Mimark

GyLDa turns protein biomarkers found in gynecological fluids into validated immunoassays: reproducible, stable and ready for clinical laboratories.

GyLDEC is an IVD immunoassay to aid the detection of endometrial cancer in post-menopausal women with abnormal uterine bleeding, using uterine fluid.

Endometriosis affects 1 in 10 women and takes 4 to 11 years to diagnose. GyLDEndo aims to enable earlier, less invasive detection from cervical fluids.

Martinez-Garcia E, Lopez-Gil C, Campoy I, Vallve J, Coll E, Cabrera S, et al. Advances in endometrial cancer protein biomarkers for use in the clinic. Expert Rev Proteomics. 2018;15(1):81-99.

Martinez-Garcia E, Lesur A, Devis L, Campos A, Cabrera S, van Oostrum J, et al. Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples. Oncotarget. 2016;7(33):53102-15.

Campoy I. Exosomes in uterine aspirates: characterization and identification of diagnostic and prognostic biomarkers in endometrial cancer [dissertation]. Barcelona: Universitat Autònoma de Barcelona; 2017.

Mimark hires professionals to innovate in women’s health through science and care.

Mimark combines scientists, clinicians, and innovators to advance gynecological diagnostics.

Mimark is a biotechnology company founded in 2021 as a spin-off of the Vall d'Hebron Institute of Research in Barcelona to improve gynecological diagnosis.

Mimark Diagnostics is based at the Parc Científic de Barcelona.

Mimark develops protein-based diagnostics to diagnose gynecological diseases from a simple, minimally invasive fluid sample. Simpler, safer, more human.